Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-4199 for Bipolar I Depression
NCT03543410Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jun 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of SEP-4199 in bipolar I disorder (3 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 6 weeks. Started Jun 2018; status: completed.
02
Drugs
SEP-4199
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT03543410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03543410.